AstraZeneca PLC may have included "outdated" information from its coronavirus vaccine trial when reporting the results, possibly providing an "incomplete view of the efficacy data," the U.S. National Institute of Allergy and Infectious Diseases said Tuesday.The questions were raised after the British biopharmaceutical company announced Monday that its vaccine was 79 percent effective in preventing the disease caused by the novel coronavirus in a clinical trial conducted in the United States and two South American countries. The company has also said experts have identified no safety concer…READ FULL ARTICLE
